TY - JOUR
T1 - Association between AXL, Hippo transducers and survival outcomes in male breast cancer
AU - Di Benedetto, Anna
AU - Mottolese, Marcella
AU - Sperati, Francesca
AU - Ercolani, Cristiana
AU - Di Lauro, Luigi
AU - Pizzuti, Laura
AU - Vici, Patrizia
AU - Terrenato, Irene
AU - Shaaban, Abeer M
AU - Humphries, Matthew P
AU - Sundara Rajan, Sreekumar
AU - Barba, Maddalena
AU - Speirs, Valerie
AU - De Maria Marchiano, Ruggero
AU - Maugeri Saccà, Marcello
PY - 2016
Y1 - 2016
N2 - Male breast cancer (MBC) is an uncommon malignancy. We have previously reported\r\nthat the expression of the Hippo transducers TAZ/YAP and their target CTGF was\r\nassociated with inferior survival in MBC patients. Preclinical evidence\r\ndemonstrated that Axl is a transcriptional target of TAZ/YAP. Thus, we herein\r\nassessed AXL expression to further investigate the significance of active\r\nTAZ/YAP-driven transcription in MBC. For this study, 255 MBC samples represented \r\nin tissue microarrays were screened for AXL expression, and 116 patients were\r\nincluded. The association between categorical variables was verified by the\r\nPearson's Chi-squared test of independence (2-tailed) or the Fisher Exact test.\r\nThe relationship between continuous variables was tested with the Pearson's\r\ncorrelation coefficient. The Kaplan-Meier method was used for estimating survival\r\ncurves, which were compared by log-rank test. Factors potentially impacting\r\n10-year and overall survival were verified in Cox proportional regression models.\r\nAXL was positively associated with the TAZ/CTGF and YAP/CTGF phenotypes\r\n(p = 0.001 and p = 0.002, respectively). Patients with TAZ/CTGF/AXL- or\r\nYAP/CTGF/AXL-expressing tumors had inferior survival compared with\r\nnon-triple-positive patients (log rank p = 0.042 and p = 0.048, respectively).\r\nThe variables TAZ/CTGF/AXL and YAP/CTGF/AXL were adverse factors for 10-year\r\nsurvival in the multivariate Cox models (HR 2.31, 95%CI:1.02-5.22, p = 0.045, and\r\nHR 2.27, 95%CI:1.00-5.13, p = 0.050). Nearly comparable results were obtained\r\nfrom multivariate analyses of overall survival. The expression pattern of AXL\r\ncorroborates the idea of the detrimental role of TAZ/YAP activation in MBC.\r\nOverall, Hippo-linked biomarkers deserve increased attention in this rare\r\ndisease. This article is protected by copyright. All rights reserved.
AB - Male breast cancer (MBC) is an uncommon malignancy. We have previously reported\r\nthat the expression of the Hippo transducers TAZ/YAP and their target CTGF was\r\nassociated with inferior survival in MBC patients. Preclinical evidence\r\ndemonstrated that Axl is a transcriptional target of TAZ/YAP. Thus, we herein\r\nassessed AXL expression to further investigate the significance of active\r\nTAZ/YAP-driven transcription in MBC. For this study, 255 MBC samples represented \r\nin tissue microarrays were screened for AXL expression, and 116 patients were\r\nincluded. The association between categorical variables was verified by the\r\nPearson's Chi-squared test of independence (2-tailed) or the Fisher Exact test.\r\nThe relationship between continuous variables was tested with the Pearson's\r\ncorrelation coefficient. The Kaplan-Meier method was used for estimating survival\r\ncurves, which were compared by log-rank test. Factors potentially impacting\r\n10-year and overall survival were verified in Cox proportional regression models.\r\nAXL was positively associated with the TAZ/CTGF and YAP/CTGF phenotypes\r\n(p = 0.001 and p = 0.002, respectively). Patients with TAZ/CTGF/AXL- or\r\nYAP/CTGF/AXL-expressing tumors had inferior survival compared with\r\nnon-triple-positive patients (log rank p = 0.042 and p = 0.048, respectively).\r\nThe variables TAZ/CTGF/AXL and YAP/CTGF/AXL were adverse factors for 10-year\r\nsurvival in the multivariate Cox models (HR 2.31, 95%CI:1.02-5.22, p = 0.045, and\r\nHR 2.27, 95%CI:1.00-5.13, p = 0.050). Nearly comparable results were obtained\r\nfrom multivariate analyses of overall survival. The expression pattern of AXL\r\ncorroborates the idea of the detrimental role of TAZ/YAP activation in MBC.\r\nOverall, Hippo-linked biomarkers deserve increased attention in this rare\r\ndisease. This article is protected by copyright. All rights reserved.
KW - AXL
KW - Hippo Pathway
KW - Male Breast Cancer
KW - TAZ
KW - YAP
KW - AXL
KW - Hippo Pathway
KW - Male Breast Cancer
KW - TAZ
KW - YAP
UR - https://publicatt.unicatt.it/handle/10807/93754
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85014261275&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85014261275&origin=inward
U2 - 10.1002/jcp.25745
DO - 10.1002/jcp.25745
M3 - Article
SN - 0021-9541
SP - N/A-N/A
JO - Journal of Cellular Physiology
JF - Journal of Cellular Physiology
IS - N/A
ER -